Eli Lilly news from FierceBiotech
NewsFDA delays review of Eli Lilly’s would-be blockbuster
Shares of Eli Lilly slipped slightly after the FDA announced that it would extend its review of the closely watched anti-clotting drug prasugrel by three months. Daiichi Sankyo and Lilly both believe Read more...
Lilly pays $35M to land TransPharma pact
Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its Read more...
Itero raises $21M; Immunicon files for Chapter 11; AVI cuts staff;
> San Mateo, CA-based Itero has formed a collaboration with India's Biological E. Limited and raised $21 million in a Series A. Read more...
ALSO NOTED: ASCO already churning out news; Lilly, FDA ironing out Zyprexa shot problems; and much more...
> Today marks the start of the annual ASCO. Here's a round-up of some of the news coming out of the conference. Read more...
Sun to Taro: Too late to call off merger
It's too late to stop now, according the Sun Pharmaceuticals. Yesterday, Taro Pharmaceuticals said it was backing out of a planned merger with Sun because the move was not in the best interest of its Read more...
ALSO NOTED: FDA, Medicare team up on drug surveillance; Early stage prostate vaccine shows promise; and much more...
> FDA is teaming up with the Center for Medicare and Medicaid Services on data-mining. FDA will be able to probe CMS's patient databases, actively looking for potential safety problems. Next, the Read more...
Eli Lilly shakes up R&D ops in restructuring
Eli Lilly has shaken up the management structure of its R&D and international operations as it looks for a more efficient way to speed new drugs through the approval process. Its worldwide Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Read more...
ALSO NOTED: Lilly completes massive expansion project; Revance garners new venture funds; Gamers target protein chemistry; and
> After laboring for 10 long years, Eli Lilly says it's wrapped a massive, $1 billion expansion program for its new research hub. Read more...
| Press ReleasesLilly Completes Final Phase of Its Indianapolis Biotechnology ComplexLilly Completes Final Phase of Its Indianapolis Biotechnology ComplexMay 12, 2008 Completion honors Lilly's commitment to the community and its biotech pipelineINDIANAPOLIS, May 12, 2008 Read more... FDA Approves Cialis (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction FDA Approves Cialis (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction -Approval Makes Available New Daily Dosing Option for the Treatment of ED- INDIANAPOLIS, Jan 08, 2008 -- Read more... Daiichi Sankyo, Lilly Submit NDA for Investigational Antiplatelet Drug, Prasugrel, to FDA Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name Read more... PRESS RELEASE: Galapagos NV in Osteoporosis Deal with Eli Lilly and Company Galapagos NV in Osteoporosis Deal with Eli Lilly and Company Mechelen, Belgium; 19 December 2007 - Galapagos announced today that it has entered into a global collaboration agreement with Eli Lilly Read more... PRESS RELEASE: Ambrx Announces Drug Discovery Alliance With Eli Lilly and Company Ambrx Announces Drug Discovery Alliance With Eli Lilly and Company Ambrx to Collaborate with Lilly to Discover Protein and Antibody Drug Candidates Targeting Multiple Therapeutic Areas Using Ambrx's Read more... |
Get more Eli Lilly coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends